logo-loader
viewFutura Medical PLC

Futura Medical sees 'potentially quicker route to market' for its erectile dysfunction formulation

Futura Medical PLC's (LON:FUM) executive director and head of R&D Ken James speaks to Proactive London's Andrew Scott following the read-out from the phase III clinical trial of its erectile dysfunction gel.

James says while MED2005 showed strong efficacy, excellent safety and rapid speed of onset, the placebo had a “highly statistically significant” impact on the men in the control group of the experiment.

The placebo in this trial was DermaSys, developed by the company to deliver the active ingredient glyceryl trinitrate, or GTN for short.

Quick facts: Futura Medical PLC

Price: 11.75 GBX

AIM:FUM
Market: AIM
Market Cap: £28.82 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: SDX Energy hits stable production at South Disouq

Headlines from the Proactive UK newsroom. SDX Energy (LON:SDX) has achieved stable production at its South Disouq concession in Egypt three months earlier than initially expected. Gas has been flowing since 7 November at a fixed price.  Eco Atlantic (LON:ECO) and its partners on the...

on 10/12/19

RNS

Holding(s) in Company

6 days, 4 hours ago

Holding(s) in Company

6 days, 4 hours ago

GM Statement

1 week, 3 days ago

Second Price Monitoring Extn

2 weeks, 6 days ago

Price Monitoring Extension

2 weeks, 6 days ago

Result of Fundraising

on 23/12/19

2 min read